What Verdica's 799 score means for ARCUTIS
ARCUTIS holds a composite score of 799 out of 850, placing it in the "strong" performance band (740–799). This score reflects measured compliance across the regulatory dimensions Verdica tracks: state pharmacy board standing, FDA oversight, and DEA adherence. A score in this range suggests the entity maintains solid regulatory footing and operational standards, though it falls short of the "excellent" threshold (800–850) that indicates near-flawless compliance records.
For a business owner or consumer evaluating ARCUTIS, this score indicates a provider with demonstrated regulatory credibility. The entity is not flagged as high-risk or elevated-risk; it has cleared baseline safety and licensing hurdles. However, the gap between 799 and 850 points to room for improvement or minor compliance gaps that regulators have identified. No independent customer reviews are indexed yet, so this assessment reflects regulatory data only—not patient or client experience.
How the sub-scores break down
Product Approval (850/850): ARCUTIS scores at the maximum in this dimension, indicating all tracked products have secured required FDA approval or authorization status. In the pharmacy and pharmaceutical supply chain, product approval scores reflect whether marketed items meet federal safety, efficacy, and manufacturing standards. A perfect score here means Verdica's audit found no unapproved or misbranded products in distribution.
Manufacturer Profile (720/850): This sub-score of 720 is the lowest of the three and represents the primary factor holding the overall composite below 800. Manufacturer Profile scores typically aggregate data on facility registrations, inspection history, and operational certifications tracked by state pharmacy boards and the FDA. A score of 720 suggests ARCUTIS maintains active manufacturing registrations and meets baseline facility standards, but regulators may have flagged minor deficiencies—such as corrective actions during inspections, lapsed certifications, or non-critical observations in compliance records—that do not rise to suspension or revocation but do reduce confidence in this dimension.
FDA Compliance (830/850): This strong sub-score reflects ARCUTIS's standing in federal oversight. FDA Compliance scores pull from adverse event reporting, warning letters, enforcement actions, and inspection findings. A score of 830 indicates the entity has not triggered major red flags (such as active warning letters or recalls), though minor compliance matters may exist in the historical record.
What regulators track for pharmacy providers
State boards of pharmacy and the FDA monitor several dimensions that feed into Verdica's scoring model:
Licensing & Registration: Pharmacies and manufacturers must maintain active licenses in their operating jurisdictions. Lapses, denials, or revocations directly impact scores.
Inspection Findings: The FDA and state boards conduct facility inspections and issue observations—ranging from minor documentation gaps to serious violations. Repeated or unresolved findings lower scores; prompt corrective action preserves them.
Product Compliance: All drugs and devices must carry proper FDA status (approved, authorized, or legitimately exempt). Unapproved marketing or misbranding results in enforcement action and score penalties.
Adverse Event Reporting: Manufacturers must report safety issues to the FDA. Systemic reporting failures or patterns of underreporting trigger scrutiny.
DEA Compliance: For controlled substance handling, DEA registration, record-keeping, and distribution audits ensure no diversion or trafficking. Violations are serious and heavily penalize scores.
Recall History: Voluntary or mandated recalls indicate product or process issues and lower confidence metrics.
Bottom line
ARCUTIS presents as a strong, compliant provider based on its 799 score and perfect product approval rating, though its manufacturer profile score suggests room for operational refinement. Anyone considering a business relationship should verify current state pharmacy licenses, review publicly available FDA inspection reports, and confirm no active warning letters or recalls are in effect. The absence of customer reviews means regulatory standing is the primary data point available for due diligence.